Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
EUCRW was delisted on the 26th of April, 2023.
0 hedge funds and large institutions have $0 invested in Eucrates Biomedical Acquisition Corp. Warrant in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 22 closing their positions.
100% less funds holding
Funds holding: 22 → 0 (-22)
100% less capital invested
Capital invested by funds: $731K → $0 (-$731K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 22
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$676K |
| 2 |
DM
Deerfield Management
New York
|
-$13.5K |
| 3 |
CAC
Cowen and Company
New York
|
-$8.2K |
| 4 |
6CM
683 Capital Management
New York
|
-$7.95K |
| 5 |
ACM
Altium Capital Management
New York
|
-$4.82K |
EUCRW Hedge Fund Activity: Q2 2023 in Review
0 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) for Q2 2023, worth a combined $0 — down 100% from $731K a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of EUCRW and 0 opened new positions — a net loss of 22 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was EcoR1 Capital, exiting entirely with an estimated $676K sold.
- 0 institutional investors held Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) as of Q2 2023, down from 22 in Q1 2023.
- Funds reported $0 of Eucrates Biomedical Acquisition Corp. Warrant stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Eucrates Biomedical Acquisition Corp. Warrant positions in Q2 2023 and 22 closed out, a net change of -22 holders.
- The largest Eucrates Biomedical Acquisition Corp. Warrant seller in Q2 2023 was EcoR1 Capital, an estimated $676K sold.
Based on aggregated 13F filings for Q2 2023.